Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Shionogi Grants the Rights to BNP Assay to Bayer Corp.
July 23, 2001
- Tsuruha: Sales Up 19.5%, Net Profits Up 8.2%
July 23, 2001
- Oriental Yeast Expands Collaboration with Lexicon Genetics
July 23, 2001
- SSP Wants to Become No. 1 OTC Drug Maker
July 23, 2001
- Suzuken Aims to Become No.1 Wholesaler in 2010
July 23, 2001
- Boots-MC to Be Dissolved
July 23, 2001
- Mochida Licenses Immune Response Modifier from 3M
July 23, 2001
- Therapeutic GLs Using EBM under Preparation in 4 Fields
July 16, 2001
- WORLD NEWS IN BRIEF -2-
July 16, 2001
- Control of Total Medical Costs Has No Durable Effect: Seminar
July 16, 2001
- Japanese Global Strategy Update (4)
July 16, 2001
- Kyowa Hakko to Focus on Cancer, Allergies: President Hirata
July 16, 2001
- Bungyo to Undermine Doctors' Freedom: Dr Sugaya of JMA
July 16, 2001
- Asahi Chemical Aims to Boost Drug Sales to \80 Billion in FY2005
July 16, 2001
- JPA Opposed to JMA's Working Paper on Costs of Bungyo
July 16, 2001
- JPMA to Propose New Drug Benefit System by End of Summer
July 16, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 16, 2001
- Sumitomo Licenses Hepatitis B Drug from Novirio
July 16, 2001
- OTC NEWS IN BRIEF
July 16, 2001
- Kasamatsu Meiki, Hokuho to Merge Within the Year
July 16, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…